PATENT CLAIM ANALYSIS

Application Number: 15918699
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "178100"]

Abstract:
The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.

Claim (Index 27):
The method of  claim 16 , wherein the anti-CD28 Fab\u2032 antibody is present in a pharmaceutical composition together with one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.76923
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12710842', '13621590', '11961764', '14042205', '12880623']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7258020912606525
- 35 USC 102 Novelty (BERT): 0.5200288439486086
- Combined Prediction Score: 0.7052247665294482
- Mean Citation Score: 303.536038
- Max Citation Score: 307.80945
- Similarity Product: 205.0309467041999

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test